HPV vaccination has not yet been implemented in low- and middle-income countries with the highest cervical cancer rates. Mathematical models estimate that if 70% vaccination coverage is achieved in low- and middle-income countries, HPV vaccines

could prevent the deaths of more than 4 million women vaccinated over the next decade [107]. The GAVI Alliance has approved initial funding for HPV vaccination in eligible low-income countries, which is a major step toward ensuring universal access to HPV vaccine. However, the barriers related to providing a vaccine in early adolescence are even greater than those of including HBV vaccine in the infant immunization schedule. Barriers include difficulties Temozolomide price accessing 11–14-year-olds in areas where health-care seeking and school attendance may be low, and parental or societal hesitation related to a vaccine against STIs for adolescents. A great deal will be learned Depsipeptide chemical structure from current implementation

of HPV vaccine to inform delivery of future STI vaccines. Most STI vaccines are being developed for early adolescents, to provide maximal protection before and during the time of highest risk. For some vaccines, there may be compelling reasons for infant vaccination in addition to implementation issues, for example, an HSV vaccine that would also protect against HSV-1 infection. Nonetheless, new adolescent platforms for health intervention delivery are needed to respond to a global agenda to improve adolescent health, especially sexual and reproductive health [108]. HPV vaccine implementation is an opportunity to develop these adolescent platforms, which can be used not only for currently recommended prevention services, but also for future STI vaccines. Ergoloid Given common risk factors, high rates of co-infection, and epidemiologic overlap in STI-related complications, combination STI vaccines for adolescents would be an important future goal. HPV vaccine

implementation will also provide insight on monitoring vaccine impact, which will need to be considered for other STI vaccines well in advance of vaccine availability. In the face of almost half a billion curable STIs occurring annually [9], more than half a billion people with a viral STI at any point in time [11] and [14], and the resulting burden of STI-related complications affecting sexual, reproductive, and maternal-child health, new prevention paradigms are needed. Existing STI prevention interventions can be optimally scaled up within a broad framework of health promotion and wellness, with normalization and integration of STI services into primary and reproductive healthcare settings.